title: Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
authors.forename: Henry G
authors.initials: HG
authors.lastname: Bone
authors.forename: Arthur C
authors.initials: AC
authors.lastname: Santora
authors.forename: Arghya
authors.initials: A
authors.lastname: Chattopadhyay
authors.forename: Uri
authors.initials: U
authors.lastname: Liberman
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D019386:Alendronate